Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance

Simple item page
dc.centroFacultad de Medicinaes_ES
dc.contributor.authorGarcía Aranda, Marilina
dc.contributor.authorTéllez-Santana, Teresa
dc.contributor.authorMcKenna, Lauraine
dc.contributor.authorRedondo-Bautista, Maximino
dc.date.accessioned2022-06-15T12:52:03Z
dc.date.available2022-06-15T12:52:03Z
dc.date.issued2022-04-30
dc.departamentoEspecialidades Quirúrgicas, Bioquímica e Inmunología
dc.description.abstractNowadays, the identification of new therapeutic targets that allow for the development of treatments, which as monotherapy, or in combination with other existing treatments can contribute to improve response rates, prognosis and survival of oncologic patients, is a priority to optimize healthcare within sustainable health systems. Recent studies have demonstrated the role of Substance P (SP) and its preferred receptor, Neurokinin 1 Receptor (NK-1R), in human cancer and the potential antitumor activity of NK-1R antagonists as an anticancer treatment. In this review, we outline the relevant studies published to date regarding the SP/NK-1R complex as a key player in human cancer and also evaluate if the repurposing of already marketed NK-1R antagonists may be useful in the development of new treatment strategies to overcome cancer resistancees_ES
dc.description.sponsorshipThe researcher Marilina García-Aranda is the benefactor of a postdoctoral contract financed by the European Social Fund—Operational Program of Andalusia 2014–2020 for the “Incorporation of Research Personnel with a PhD degree in the field of Health Sciences and Technologies in R&D and Innovation Centers of the Public Health System of Andalusia” (RH-0055-2020). This work was partially supported by grant from the University of Malaga—Consejería de Transformación Económica, Industria, Conocimiento y Universidades—Junta de Andalucia (UMA20-FEDERJA-161). Partial funding for open access charge: Universidad de Málagaes_ES
dc.identifier.citationGarcía-Aranda M, Téllez T, McKenna L, Redondo M. Neurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistance. Cancers. 2022; 14(9):2255. https://doi.org/10.3390/cancers14092255es_ES
dc.identifier.doihttps://doi.org/10.3390/cancers14092255
dc.identifier.urihttps://hdl.handle.net/10630/24384
dc.language.isoenges_ES
dc.publisherIOAP-MPDIes_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectCánceres_ES
dc.subject.otherCanceres_ES
dc.subject.otherTachykinines_ES
dc.subject.otherTachykinin receptores_ES
dc.subject.otherNK-1Res_ES
dc.subject.otherTargeted treatmentes_ES
dc.subject.otherDrug repurposing; personalized medicinees_ES
dc.subject.otherResistancees_ES
dc.titleNeurokinin-1 Receptor (NK-1R) Antagonists as a New Strategy to Overcome Cancer Resistancees_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationbbf900b5-f320-4f99-b49e-05f2b241aea3
relation.isAuthorOfPublicationd52b6bac-766e-46b8-b985-9a17c36a322a
relation.isAuthorOfPublication.latestForDiscoverybbf900b5-f320-4f99-b49e-05f2b241aea3

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
cancers-14-02255-v2.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Artículos